{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:49:28Z","timestamp":1771883368207,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":5790,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1093\/annonc\/mdh093","type":"journal-article","created":{"date-parts":[[2004,3,3]],"date-time":"2004-03-03T19:13:19Z","timestamp":1078341199000},"page":"511-516","source":"Crossref","is-referenced-by-count":78,"title":["Rituximab\u2013EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study"],"prefix":"10.1016","volume":"15","author":[{"given":"M.","family":"Jermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.M.","family":"Jost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ch.","family":"Taverna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Jacky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.P.","family":"Honegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.C.","family":"Betticher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Egli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th.","family":"Kroner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.A.","family":"Stahel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh093_bb0010","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM199304083281409","article-title":"Treatment of non-Hodgkin\u2019s lymphoma","volume":"328","author":"Armitage","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh093_bb0015","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh093_bb0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.1998.16.1.48","article-title":"Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin\u2019s lymphoma: value of augmented preparative regimens\u2014a Southwest Oncology Group trial","volume":"16","author":"Stiff","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh093_bb0025","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh093_bb0030","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2000.18.21.3633","article-title":"Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH","volume":"18","author":"Gutierrez","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh093_bb0035","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1200\/JCO.1993.11.8.1573","article-title":"EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin\u2019s lymphoma","volume":"11","author":"Wilson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh093_bb0040","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1097-0142(19910915)68:6<1221::AID-CNCR2820680607>3.0.CO;2-R","article-title":"A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors","volume":"68","author":"Casper","year":"1991","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh093_bb0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19890101)63:1<37::AID-CNCR2820630106>3.0.CO;2-Z","article-title":"Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma","volume":"63","author":"Hortobagyi","year":"1989","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh093_bb0050","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D","article-title":"Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation","volume":"65","author":"Shapira","year":"1990","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh093_bb0055","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-96-2-133","article-title":"Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion","volume":"96","author":"Legha","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdh093_bb0060","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood.V86.4.1515.bloodjournal8641515","article-title":"Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay","volume":"86","author":"Kang","year":"1995","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh093_bb0065","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/07357909009017560","article-title":"Comprehensive criteria for assessing therapy-induced toxicity","volume":"8","author":"Ajani","year":"1990","journal-title":"Cancer Invest"},{"key":"10.1093\/annonc\/mdh093_bb0070","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3816\/CLM.2001.n.003","article-title":"A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin\u2019s lymphoma","volume":"1","author":"Wilder","year":"2001","journal-title":"Clin Lymphoma"},{"key":"10.1093\/annonc\/mdh093_bb0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00000421-199502000-00009","article-title":"Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma","volume":"18","author":"Carrion","year":"1995","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdh093_bb0080","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh093_bb0085","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP\u2014an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh093_bb0090","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00130404-200209000-00007","article-title":"Rituximab for aggressive non-Hodgkin\u2019s lymphomas relapsing after or refractory to autologous stem cell transplantation","volume":"8","author":"Pan","year":"2002","journal-title":"Cancer J"},{"key":"10.1093\/annonc\/mdh093_bb0095","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/sonc.2002.30151","article-title":"The role of rituximab and chemotherapy in aggressive B-cell lymphoma a preliminary report of dose-adjusted EPOCH-R","volume":"29","author":"Wilson","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh093_bb0100","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1200\/JCO.1993.11.10.1846","article-title":"High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin\u2019s lymphoma","volume":"11","author":"Vose","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh093_bb0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh093_bb0110","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh093_bb0115","series-title":"Mantle cell lymphoma \u2013 high rates of complete remission and prolonged failure-free survival with Rituxan-HyperCVAD without stem cell transplant. Annual meeting of the American Society of Hematology. Orlando, Florida","author":"Romaguera","year":"2001"},{"key":"10.1093\/annonc\/mdh093_bb0120","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419641414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419641414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/3\/511\/557947\/mdh093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T02:15:27Z","timestamp":1582251327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419641414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0923753419641414"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh093","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}